SHYNDEC(SH:600420) Zhi Tong Cai Jing·2025-10-10 09:36Core Viewpoint - The approval of the active pharmaceutical ingredient (API) Sitagliptin Phosphate by the National Medical Products Administration (NMPA) signifies a significant advancement for the company, enhancing its portfolio in specialty APIs for diabetes treatment [1] Company Summary - The company, through its wholly-owned subsidiary China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (referred to as Weichida), has received the approval notice for the marketing application of Sitagliptin Phosphate [1] - Sitagliptin Phosphate is classified as a DPP-4 inhibitor, primarily used for improving blood sugar control in patients with type 2 diabetes [1] - The approval indicates that the API meets the regulatory requirements for drug registration in China, allowing it to be marketed domestically [1] Industry Summary - The approval of Sitagliptin Phosphate will contribute to the diversification of the company's specialty API product offerings, particularly in the diabetes treatment sector [1]